Search
Contact
15.12.2015 | KPMG Law Insights

Investment Law – Investment | Law | Compact – Issue 12/2015

Dear Readers,

A year ago, we launched our monthly newsletter Investment | Recht | Kompakt . We hope to have provided you with useful information and contributions this year. By the way: We are always happy to receive feedback on our newsletter!

Looking back, it was a year of many regulatory measures. However, 2016 will in all likelihood be no different from the previous year in this respect. Already in the next few months, a lot of work awaits the UCITS capital management companies, as UCITS V must be implemented by March 2016. In addition, the implementation of MiFID2 will still involve some effort.

But first, we wish you happy holidays and a prosperous new year!

With warm regards

Henning Brockhaus

National legislation

BaFin comments on approval procedure for investment terms and conditions of UCITS

In a letter to the investment industry, BaFin has commented on the conversion procedure of the UCITS investment conditions to the KAGB as amended by the UCITS V Conversion Act (OGAW V-UmsG). The background is the very short changeover period until March 18, 2016. On this date, the adjusted UCITS investment conditions must enter into force.

Due to the tight implementation period in combination with the expected number of amendments, the legislator has provided for the transitional provision of section 355 (5) KAGB draft in the government draft of the UCITS V Conversion Act. According to this regulation, only those amendments to the investment conditions may be applied for which are mandatory for the adaptation to the requirements of the version of the KAGB applicable as of March 18, 2016.

BaFin now provides details of its administrative practice with regard to the required amendments. According to this, the investment conditions must first be coordinated electronically with the supervisory authority. Subsequently, the capital management companies must submit written applications for approval. However, these are not to be submitted until February 22, 2016. Applications received by BaFin before this date would have to receive a negative decision from the supervisory authority, because otherwise they would be considered approved after four weeks (approval fiction, Section 163 (2) sentence 5 KAGB), but there is no legal basis for an approval of UCITS V investment conditions until March 18, 2016.

By this date, the sales prospectuses and key investor information of all UCITS must then also be revised and subsequently submitted to BaFin.

We will be happy to support and advise you on any implementation measures that may arise. Feel free to contact us.

European legislation

EU Parliament and EU Commission Consider Postponement of MiFID2

European legislators are considering postponing the planned start date of January 3, 2017 for the introduction of MiFID2 and MiFIR. The main reason for this is the costly implementation of IT infrastructure.

However, no final decision has been made yet. Please contact us if you have any questions. We will also keep you up to date here.

ESMA

Update of the Q&A catalog on the application of the AIFMD

On December 2, 2015, ESMA amended its Q&A catalog on the application of the AIFM Directive to include additional questions and answers on reporting.

You can find the updated Q&A catalog here.

Explore #more

22.01.2025 | KPMG Law Insights

The EU packaging regulation sets strict requirements for packaging

The EU has adopted the Packaging Regulation. After the European Parliament adopted the Commission’s draft on April 24, 2024, the EU member states also approved…

09.01.2025 | In the media

KPMG Law strengthens Legal Transformation Managed Services and Legal Corporate Services with two new senior managers

On January 1, KPMG Law strengthened its Transformation Managed Services practice with Jana Sichelschmidt and its Corporate Services practice with Dr. Michaela Lenk. Both are…

06.01.2025 | Deal Notifications

KPMG Law advises on the sale of Käppler & Pausch GmbH

Gabriel Pausch, the co-founder and main shareholder of Käppler & Pausch GmbH, a system supplier for metal assemblies as well as metal and sheet metal…

03.01.2025 | In the media

Interview in Betrieb on the EU money laundering package and its impact

The EU anti-money laundering package harmonizes anti-money laundering and counter-terrorism rules in Europe and introduces new measures such as cash limits of €10,000, identification requirements…

02.01.2025 | In the media

KPMG Law Statement in eMagazin Immobilienanwälte: Creativity meets law in trademark protection

Four Frankfurt, Elbtower, Vonovia: real estate projects and companies are backed by constructs worth millions or even billions. In order to stand out from the…

20.12.2024 | Deal Notifications

KPMG and KPMG Law supported the sale of circular Informationssysteme to the teccle group

Together with the corporate finance/M&A advisors of KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG), KPMG Law Rechtsanwaltsgesellschaft mbH (KPMG Law) advised the shareholders of circular Informationssysteme GmbH (circular)…

19.12.2024 | Press releases

KPMG Law defends Federal Motor Transport Authority against claim for damages in connection with the emissions scandal

The state is not liable to vehicle purchasers for damages. KPMG Law has defended the Federal Motor Transport Authority (KBA) against a civil plaintiff’s state…

18.12.2024 | KPMG Law Insights, KPMG Law Insights

MiCAR – What the new EU regulation means for crypto service providers and issuers

An EU regulation will soon come into force that will regulate crypto assets uniformly throughout Europe. It contains significant new obligations for issuers and crypto…

16.12.2024 | Deal Notifications

KPMG Law advises CERTANIA Holding GmbH on the acquisition of RASG Holdco Ltd.

KPMG Law Rechtsanwaltsgesellschaft mbH (KPMG Law) has provided legal advice to CERTANIA Holding GmbH, a platform of the Munich-based PE firm Greenpeak Partners, on the…

04.12.2024 | Deal Notifications

KPMG Law and KPMG advises Brain Biotech AG on license agreements and monetization of license rights

KPMG Law Rechtsanwaltsgesellschaft mbH and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) advised Brain Biotech AG on the monetization of licensing rights with Royalty Pharma and the conclusion…

Contact

Henning Brockhaus

Partner

THE SQUAIRE Am Flughafen
60549 Frankfurt am Main

Tel.: +49 69 951195061
hbrockhaus@kpmg-law.com

© 2024 KPMG Law Rechtsanwaltsgesellschaft mbH, associated with KPMG AG Wirtschaftsprüfungsgesellschaft, a public limited company under German law and a member of the global KPMG organisation of independent member firms affiliated with KPMG International Limited, a Private English Company Limited by Guarantee. All rights reserved. For more details on the structure of KPMG’s global organisation, please visit https://home.kpmg/governance.

 KPMG International does not provide services to clients. No member firm is authorised to bind or contract KPMG International or any other member firm to any third party, just as KPMG International is not authorised to bind or contract any other member firm.

Scroll